| 0 (0%) | 12-05 09:28 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.23 | 1-year : | 1.44 |
| Resists | First : | 1.05 | Second : | 1.23 |
| Pivot price | 0.77  |
|||
| Supports | First : | 0.77 | Second : | 0.6 |
| MAs | MA(5) : | 0.86 | MA(20) : | 0.77 |
| MA(100) : | 1.03 |
MA(250) : | 1.83 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 71.4 | D(3) : | 71.4 |
| RSI | RSI(14): 54.2 | |||
| 52-week | High : | 3.73 | Low : | 0.6 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ZIOP ] has closed below upper band by 22.6%. Bollinger Bands are 7.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0 - 0 | 0 - 0 |
| Low: | 0 - 0 | 0 - 0 |
| Close: | 0 - 0 | 0 - 0 |
Thu, 07 Apr 2022
CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer - PR Newswire
Wed, 26 Jan 2022
Ziopharm Rebrands As Alaunos Therapeutics - Yahoo Finance
Wed, 29 Jan 2020
Do Institutions Own Shares In ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)? - simplywall.st
Mon, 28 Nov 2016
Actionable Ideas in the Biotechnology and Pharmaceutical Sectors (Incl. Insider Buying): November 28 - Smartkarma
Fri, 19 Aug 2016
Here Are the Stocks You Can Trade on IEX’s New Stock Exchange - Fortune
Fri, 20 Mar 2015
Three trades to go before the closing bell - CNBC
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 216 (M) |
| Held by Insiders | 1.7244e+008 (%) |
| Held by Institutions | 9.9 (%) |
| Shares Short | 32,730 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.566e+007 |
| EPS Est Next Qtrly | -0.15 |
| EPS Est This Year | -0.57 |
| EPS Est Next Year | -0.61 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -22 % |
| Return on Assets (ttm) | 103.5 % |
| Return on Equity (ttm) | -39.4 % |
| Qtrly Rev. Growth | 398000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -48.01 |
| EBITDA (p.s.) | -3.01143e+007 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -63 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 4.73 |
| Dividend | 0 |
| Forward Dividend | 3.452e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|